Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates Transformational Quarter Marked by Clinical Validation, Regulatory Progress, and Strategic Momentum in Commercial AI Platform Launch Lantern Pharma Q3 2025 - Financial Results & Business Highlights p.1 Exhibit 99.1 Clinical Pipeline Developments LP-184: Detailed Phase 1a Results Demonstrate Clinical Proof-of-Concept & Activity In September, Lantern announced the completion of enrollment and initial clinical results fro ...